Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Cofetuzumab pelidotin
Другие языки:

    Cofetuzumab pelidotin

    Подписчиков: 0, рейтинг: 0
    Cofetuzumab pelidotin
    Cofetuzumab pelidotin.svg
    Monoclonal antibody
    Type ?
    Source Humanized (from mouse)
    Target protein tyrosine kinase 7
    Clinical data
    Other names PF-06647020
    ATC code
    • none
    Identifiers
    CAS Number
    ChemSpider
    • none
    UNII
    KEGG
    Chemical and physical data
    Formula C6774H10418N1778O2096S46
    Molar mass 151776.97 g·mol−1

    Cofetuzumab pelidotin (INN; development code PF-06647020) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.

    Antibody-drug conjugates use a monoclonal antibody that binds to tumors cells linked to a cytotoxic drug that then kills the cells. This allows the drug to selectively target the cells that the antibody binds to.

    PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer. Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies.


    Новое сообщение